FibroDx is a clinical-stage biopharmaceutical company developing imaging diagnostics based on its proprietary nanobodies (single domain antibodies) platform.
FibroDx is targeting fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis, renal fibrosis and several solid cancers with fibrotic stroma, with a special focus on colon cancer.

The FibroDx technology platform is based on the screening and selection of nanobodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can bind a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach using the same single domain antibody for patient identification, targeted therapy and disease monitoring.